Cancer vaccines have become increasingly promising and plausible combinations with surgery, chemotherapy and radiation treatments. Cancer vaccines hold the greatest promise as adjuvant treatments, when tumor burden is low and the vaccine is used to eradicate minimal residual disease following first-line treatments.
Watch this MRI video to see how a DepoVax-based vaccine candidate eliminates a tumor in real time.
Testing the safety of a therapeutic vaccine targeting breast, ovarian and prostate cancer in a Phase 1 study: Click here to learn more.
DPX-0907 is therapeutic cancer vaccine directed against breast, ovarian and prostate cancers. The vaccine is a combination of Immunovaccine's DepoVax™ delivery and enhancement technology and seven cancer specific antigens.
We believe DPX-0907 will be successful because of Immunovaccine’s superior DepoVax™ delivery technology, which we have shown has a stronger immune activating potential than the conventional formulation used in the clinic today. The seven cancer antigens used in DPX-0907 are highly specific, visible to the immune system and represent the six major cancer pathways. The combination has the ability to reduce the corresponding suppressive regulatory T-cell response.
Immunovaccine has completed proof-of-concept and safety studies for the vaccine and has manufactured large batches of the product at a cGMP facility using the company's own equipment. Therefore, Immunovaccine has completed the necessary IND-enabling steps for this product. With the green light from the FDA, the company is leading a Phase 1 clinical trial using DPX-0907 in late stage cancer patients. We have the confidence that we will be successful where others have not.